Rehmann Capital Advisory Group trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 2.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,069 shares of the biopharmaceutical company's stock after selling 341 shares during the quarter. Rehmann Capital Advisory Group's holdings in Bristol-Myers Squibb were worth $1,314,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BMY. Resonant Capital Advisors LLC grew its position in shares of Bristol-Myers Squibb by 0.3% in the second quarter. Resonant Capital Advisors LLC now owns 42,297 shares of the biopharmaceutical company's stock valued at $3,280,000 after purchasing an additional 134 shares during the last quarter. MV Capital Management Inc. grew its position in shares of Bristol-Myers Squibb by 10.7% in the first quarter. MV Capital Management Inc. now owns 1,391 shares of the biopharmaceutical company's stock valued at $102,000 after purchasing an additional 135 shares during the last quarter. Providence Wealth Advisors LLC grew its position in shares of Bristol-Myers Squibb by 0.5% in the first quarter. Providence Wealth Advisors LLC now owns 27,047 shares of the biopharmaceutical company's stock valued at $1,997,000 after purchasing an additional 139 shares during the last quarter. Rise Advisors LLC grew its position in shares of Bristol-Myers Squibb by 16.0% in the second quarter. Rise Advisors LLC now owns 1,007 shares of the biopharmaceutical company's stock valued at $78,000 after purchasing an additional 139 shares during the last quarter. Finally, Cornerstone Wealth Group LLC grew its position in Bristol-Myers Squibb by 4.9% during the second quarter. Cornerstone Wealth Group LLC now owns 2,982 shares of the biopharmaceutical company's stock worth $230,000 after buying an additional 140 shares in the last quarter. 76.54% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

NYSE:BMY opened at $81.13 on Friday. Bristol-Myers Squibb has a 1 year low of $55.76 and a 1 year high of $81.43. The firm has a 50 day moving average of $74.98 and a 200-day moving average of $74.26. The company has a current ratio of 1.42, a quick ratio of 1.31 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $172.50 billion, a P/E ratio of 26.43, a price-to-earnings-growth ratio of 1.91 and a beta of 0.40.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, November 1st. Investors of record on Friday, October 7th were issued a $0.54 dividend. This represents a $2.16 dividend on an annualized basis and a dividend yield of 2.66%. The ex-dividend date was Thursday, October 6th. Bristol-Myers Squibb's dividend payout ratio is currently 70.36%.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Ann Powell sold 25,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $70.75, for a total value of $1,768,750.00. Following the completion of the sale, the executive vice president now owns 50,476 shares of the company's stock, valued at $3,571,177. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Bristol-Myers Squibb news, EVP Ann Powell sold 25,000 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $70.75, for a total transaction of $1,768,750.00. Following the completion of the sale, the executive vice president now owns 50,476 shares of the company's stock, valued at approximately $3,571,177. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David V. Elkins sold 133,951 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, September 13th. The stock was sold at an average price of $71.30, for a total transaction of $9,550,706.30. Following the sale, the chief financial officer now directly owns 100,460 shares of the company's stock, valued at approximately $7,162,798. The disclosure for this sale can be found here. Insiders sold a total of 296,111 shares of company stock valued at $21,582,900 over the last quarter. Corporate insiders own 0.09% of the company's stock.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of recent research reports. BMO Capital Markets lifted their target price on Bristol-Myers Squibb from $92.00 to $94.00 and gave the stock an "outperform" rating in a research report on Monday, September 12th. Barclays cut their price target on shares of Bristol-Myers Squibb from $69.00 to $66.00 and set an "equal weight" rating for the company in a research note on Wednesday, October 12th. Credit Suisse Group began coverage on shares of Bristol-Myers Squibb in a research note on Thursday, November 17th. They set a "neutral" rating and a $78.00 price target for the company. StockNews.com began coverage on shares of Bristol-Myers Squibb in a research note on Wednesday, October 12th. They set a "strong-buy" rating for the company. Finally, Atlantic Securities raised their price target on shares of Bristol-Myers Squibb from $85.00 to $88.00 and gave the stock an "overweight" rating in a research note on Thursday, November 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of "Moderate Buy" and an average price target of $79.00.

About Bristol-Myers Squibb

(Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Featured Stories

• Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
• Why CSL Ltd Stock Could Be Worth a Look
• MarketBeat: Week in Review 11/28 – 12/02
• Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
• Institutions Are Buying Ambarella, Should You?
• Can ZIM Defy Broad Downturn In The Container Shipping Industry?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Get Rating).

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.